Does Rallies show 13F holders for DMAC?

Yes. Rallies tracks hedge fund and 13F ownership data for DMAC, including fund names, share counts, latest tracked quarter, and position changes when available.

Is DMAC research on Rallies investment advice?

No. Rallies provides research, data, and educational context for DMAC. It does not provide personalized investment advice.

DMAC (DiaMedica Therapeutics Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

DiaMedica Therapeutics Inc. Common Stock (DMAC) is a publicly traded Healthcare sector company. As of May 20, 2026, DMAC trades at $5.58 with a market cap of $306.06M and a P/E ratio of -8.07. DMAC moved +0.72% today. Year to date, DMAC is -29.76%; over the trailing twelve months it is +30.45%. Its 52-week range spans $3.19 to $10.42. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces DMAC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns DMAC stock?

Hedge funds tracked by Rallies that own DMAC include Cooperman Leon. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for DiaMedica Therapeutics Inc. Common Stock.

DMAC Key Metrics

Key financial metrics for DMAC
Metric	Value
Price	$5.58
Market Cap	$306.06M
P/E Ratio	-8.07
EPS	$-0.70
Dividend Yield	0.00%
52-Week High	$10.42
52-Week Low	$3.19
Volume	69.20K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-32.77M
Gross Margin	0.00%

Top Hedge Funds Holding DMAC

Cooperman Leon holds 2.02M shares of DMAC, changed +0.00% as of Mar 31, 2026.

Latest DMAC News

DiaMedica Reaches 75% Enrollment and Schedules DSMB Interim Analysis — May 20, 2026
$59.9M Cash Reserves and Positive DM199 Phase 2 Preeclampsia Data — Mar 31, 2026
DiaMedica Secures Health Canada Clearance for Phase 2 Preeclampsia Trial — Mar 5, 2026

Recent DMAC Insider Trades

STAHLBERG JAN bought 73.10K (~$626.82K) on Nov 25, 2025.
STAHLBERG JAN bought 40.25K (~$317.72K) on Nov 24, 2025.
STAHLBERG JAN bought 208.87K (~$1.55M) on Nov 21, 2025.

DMAC Analyst Consensus

3 analysts cover DMAC: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.

Common questions about DMAC

Who owns DMAC stock?: Hedge funds tracked by Rallies that own DMAC include Cooperman Leon. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for DiaMedica Therapeutics Inc. Common Stock.
Does Rallies show 13F holders for DMAC?: Yes. Rallies tracks hedge fund and 13F ownership data for DMAC, including fund names, share counts, latest tracked quarter, and position changes when available.
Is DMAC research on Rallies investment advice?: No. Rallies provides research, data, and educational context for DMAC. It does not provide personalized investment advice.